Work for Rubius Therapeutics?

Claim Your Profile

Rubius Therapeutics Logo Image

Rubius Therapeutics

Rubius Therapeutics Banner Image

About Rubius Therapeutics

51-200 Employees
Based in Cambridge, Massachusetts

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Their proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Their initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. They plan to file their first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. They are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond.

Ticker:
RUBY
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol